What it sells
AI for drug discovery.
Business model breakdown
Buyer: who owns the budget?
Pharma R&D partners (Novartis, Eli Lilly, Johnson & Johnson).
Workflow: what inputs become what output?
Partners and Isomorphic run joint small-molecule discovery programs against targets using Isomorphic AI models for molecule design and property prediction.
Economics: what it saves and how it charges
Research collaborations with pharma; Novartis deal expanded to up to three additional programs. Financial terms not published on site.
Distribution: how it reaches customers
Direct partnerships with pharma, biotech and CROs.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-10-14 | — | — | — | news.google.com |
| 2026-10-09 | — | — | — | news.google.com |
| 2026-10-08 | — | — | — | news.google.com |
| 2026-05-13 | — | 2,1 milliards de dollars | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-17.